<DOC>
	<DOCNO>NCT00002168</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness two anti-HIV drug combination give HIV-infected patient never treat anti-HIV drug . One drug combination stavudine ( d4T ) plus didanosine ( ddI ) plus Crixivan . The combination Retrovir ( AZT ) plus Epivir ( 3TC ) plus Crixivan .</brief_summary>
	<brief_title>A Comparison Two Anti-HIV Triple-Drug Combinations HIV-Infected Patients</brief_title>
	<detailed_description>100 patient randomized receive Zerit ( Stavudine ) + Videx ( Didanosine ) + Crixivan ( Indinavir ) 100 patient randomized receive Retrovir ( Zidovudine ) + Epivir ( Lamivudine ) + Crixivan ( Indinavir ) . Patients treat 48 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . CD4 cell count 200 700 cells/mm3 . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : AIDS define condition within 1 month study entry . Prior Medication : Excluded : Patients history antiretroviral therapy treatment .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>